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Abstract
Background: The combination of capecitabine and gemcitabine at Fixed Dose Rate (FDR) has
been demonstrated to be well tolerated, with apparent efficacy in patients with advanced cancers.
FDR gemcitabine infusion leads to enhanced intracellular accumulation of drug and possible
augmented clinical effect. The goals of this phase I study were to determine the maximum-tolerated
dose (MTD) of chronomodulated capecitabine in patients with advanced cancer and to describe
the dose-limiting toxicities (DLT), the safety profile of this way of administration.
Methods: Patients with advanced solid tumours who had failed to response to standard therapy
or for whom no standard therapy was available were elegible for this study. Capecitabine was
administered orally according to following schedule: 1/4 of dose at 8:00 a.m.; 1/4 of dose at 6:00
p.m. and 1/2 of dose at 11:00 p.m. each day for 14 consecutive days, followed by a 7-day rest period.
Results: All 27 patients enrolled onto the study were assessable for toxicity. The most common
toxicities during the first two cycles of chemotherapy were fatigue, diarrhoea and hand foot
syndrome (HFS). Only one out of the nine patients treated at capecitabine dose of 2,750 mg/m2
met protocol-specified DLT criteria (fatigue grade 4). However, at these doses the majority of
cycles of therapy were delivered without dose reduction or delay. No other episodes of DLT were
observed at the same dose steps and at the lower dose steps of capecitabine (1,500/1,750/2,000/
2,250/2,500 mg/m2). The dose of 2,750 mg/m2 is recommended for further study. Tumor responses
were observed in patients with metastatic breast and colorectal cancer.
Conclusion: High doses of chronomodulated capecitabine can be administered with acceptable
toxicity. The evidence of antitumor activity deserves further investigation in phase II combination
chemotherapy studies.
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Background
Until recently, 5-fluorouracil (5-FU)-based therapy was
the only drug regularly used for the palliation of patients
with the most common types of cancer, such as colorectal,
breast and stomach cancer, and it has been reported to
have a limited impact on survival [1]. The overall treat-
ment results remained unsatisfactory. It has only achieved
10% of objective responses, when given as a single agent
for first-line treatment of metastatic disease [2,3]. The
introduction into clinical practice of more effective treat-
ment regimes with 5-FU, as the use of prolonged continu-
ous infusion or the combination with other drugs, has led
to an increase of responses [4-13]
Capecitabine, a carbamate derivative of 5'-DFUR, is
absorbed through the gastrointestinal mucosa as an intact
molecule and thereby it avoids the gastrointestinal toxic-
ity associated with 5'DFUR. Infact, it is sequentially acti-
vated by carboxylesterase, cytidine deaminase and
pyrimidine nucleoside phosphorylase. This cascade
results in the formation of 5'-deoxy-5-fluorocytidine (5'-
DFCR), 5'-deoxy-5-fluorouridine (5'-DFUR) and finally
the intratumoral release of 5-FU [14]. Thymidilate phos-
phorylase (TP) catalyses the final step of capecitabine acti-
vation from the intermediate metabolite 5-
deoxyfluorouracil to fluorouracil. 5-FU derived from the
conversion acts on Thymidylate synthase (TS) and it is cat-
alyzed by Dihydropyrimidine dehydrogenase (DPD). So
its pharmacodynamic is similar to intravenous 5-FU [14].
In human colon cancer xenograft models, capecitabine
was more effective at wider dose ranges than either 5-FU
or 5'DFUR and showed a minor gastrointestinal toxicity
[15]. Capecitabine has shown response rates in metastatic
colorectal disease similar to infusional fluorouracil regi-
mens at about 25%, with acceptable toxicity, and the con-
venience of an oral administration schedule [16].
In phase I and pharmacologic study by Mackean and col-
legues, capecitabine was administered in monotherapy
twice daily as outpatient therapy, each cycle administered
for 2 weeks followed by 1 week of rest. Thirty-four patients
with advanced and/or metastatic solid tumors, all of
whom except three patients were pretreated, were treated
at dose levels from 502 to 3,514 mg/mq daily. They estab-
lished that 3,000 mg/mq was not tolerated and they
defined 2,510 mg/mq daily as the dose for phase II stud-
ies. Toxicities at this and lower dose levels were generally
mild or moderate in nature and similar to those seen with
continuous infusional 5-FU or 5'-DFUR treatment. The
main drug-related toxicities were PPE and gastrointesti-
nal, all of which were reversible and manageable with
appropriate dose interruptions and modifications. The
Authors recommended for further evaluation a dose of
2,510 mg/mq daily administered by the intermittent
schedule [17].
We have recently conducted a phase II trial based on con-
tinuous infusion of oxaliplatin plus chronomodulated
capecitabine in thirty-six 5-fluorouracil and irinotecan
resistant advanced colorectal cancer patients [18].
Chronomodulated 5-FU clinical efficacy is maximum
when administered in nocturnal hours with a concentra-
tion peak at 4:00 a.m. [19]. Capecitabine mimes continu-
ous infusion of fluorouracil and is terminally converted in
5-FU. The thymidylate synthase (TP) is the enzyme
responsible for this drug conversion and has not shown
any specific circadian rhythm. The rational of capecitab-
ine administration especially in nocturnal hours (1/4
dose at 6:00 p.m. and 2/4 dose at 11:00 p.m.), as per-
formed in the mentioned study, was just based on the
attempt to mime 5-FU chronomodulated infusion [18].
In particular, we administered oxaliplatin plus a chrono-
modulated schedule of capecitabine, such as 1750 mg/
mq/die os (h 8.00 a.m. 25% of total dose; h 6.00 p.m.
25% of total dose; h 11.00 p.m. 50% of total dose), d 1–
14 every 21 days. We demonstrated a high overall tumor
growth control, a remarkable median time to progression
(TTP) and overall survival (OS) and the good safety pro-
file with diarrhoea (11.6%), nausea/vomiting (8.3%),
neuropathy (8.3%), mucositis (8.3%), asthenia (16.7%)
and hand-foot syndrome (5.5%), as most frequent related
G3-4 adverse reactions.
Based on this phase II trial and on the above considera-
tions, we conducted a phase I study aimed to determine
the maximum-tolerated dose (MTD) and dose-limiting
toxicities (DLTs) of capecitabine administered for two
cycles of chronomodulated and intermittent therapy
(two-weeks crhonomodulated oral therapy followed by 1
week of rest).
Methods
Patient selection
All patients had a baseline history and full physical exam-
ination with radiologic and laboratory evaluation.
Patients with measurable or clinically assessable histolog-
ically confirmed advanced solid tumours who hade failed
to response to standard therapy or for whom no standard
therapy was available were elegible for this study. An age
between 18 and 80 years, an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status ≤ 1 and a life
expectance > 3 months were required. Bone marrow func-
tion requirements included an absolute neutrophil count
≥ 1500/mm3, a platelet count ≥ 100000/mm3 and hemo-
globin ≥ 10.0 g/100 ml. Preserved renal function (serum
creatinine  ≤ 1.6 mg/dL, normal creatinine clearance),
hepatic function (total bilirubin ≤ 1.5 mg/dL, AST and
ALT ≤ 2,5 times normal without hepatic metastasis and ≤BMC Cancer 2006, 6:42 http://www.biomedcentral.com/1471-2407/6/42
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4 times normal with hepatic metastasis; serum alkaline
phosphatase < 2.5 times the upper limit of normal or <
five times the upper limit of normal if liver metastases
were present or < 10 times the upper limit of normal if
bone metastases were present) and cardiac function were
required.
Major exclusion criteria included cytotoxic or radiother-
apy treatment within the previous 4 weeks (6 weeks if the
previous therapy included a nitrosourea or mitomycin).
Concomitant use of amiodarone, ketoconazole, itracona-
zole, diltiazem, verapamil, barbiturates, warfarin was not
permitted. Pregnant or breast feeding woman or patients
with uncontrolled severe disease were excluded. Patients
with significant stomach, small intestine, liver, or kidney
disease likely to affect drug absorption or metabolism
were excluded from the study. Patients with history of
coagulopathy or with nervous central system tumour or
metastasis were excluded too. All patients were required to
provide written informed consent prior to initiation of
treatment, after a complete and opportune explanation.
Local ethics committee approval was obtained. Women in
fertile age had to be informed about risks incurring in case
of pregnancy. The trial was conducted in accordance with
the declaration of Helsinki. Patients were excluded if ade-
quate follow-up was not possible (environmental or geo-
graphic difficulties, no compliance to undergo necessary
clinical-instrumental investigations, etc.). The institution
that granted ethical approval for the study was University
Campus Bio-Medico of Rome. A specific informed con-
sent was obtained from each participant before study
entry.
Study design
This is an open-label, single-center, nonrandomized,
dose-escalating phase I study. All laboratory tests required
to assess eligibility had to be completed within 7 days
before start of treatment.
Capecitabine was administered orally according to fol-
lowing schedule: 1/4 of dose at 8:00 a.m.; 1/4 of dose at
6:00 p.m. and 1/2 of dose at 11:00 p.m. each day for 14
consecutive days (Days 1–14), followed by a 7-day rest
period. Each treatment cycle is repeated every 21 days.
Capecitabine was supplied as film-coated Xeloda tablets
in two dosages strengths, 150-mg and 500-mg tablets
administered not in fasting conditions, swallowed with
water. No specific pre-medication for nausea and/or vom-
iting was provided (anticipated). A preventive protonic
pump inhibitor (PPI) was advised to gastro-protective
aim.
Dose-escalation and definition of study end points
In phase I study of intermittent twice-daily oral therapy
with capecitabine in patients with advanced and/or meta-
static cancer, Mackean et al [17] used a starting dose level
of 502 to 3,514 mg/mq daily, following a modified Fibon-
acci scheme. Since 3,000 mg/mq daily was not tolerated,
they defined 2,510 mg/mq daily as the dose for phase II
studies. Considering these results, the starting dose level
in our phase I trial was 1750 mg/mq daily. The subse-
quent dose levels foreseen were: 2,000, 2,250, 2,500,
2,750, 3,000 mg/mq daily. In the absence of dose-limiting
toxicities, only three patients were to be treated at the first
two dose levels. At the third and subsequent dose levels, it
was planned to treat at least six patients because it was
anticipated that these dose levels may be therapeutic or
associated with toxicity. Patients were seen weekly and
toxicity was assessed by the National Cancer Institute of
Canada Common Toxicity Criteria (NCI-CTC). For pur-
poses of determining the MTD, only DLTs occurring dur-
ing the first two cycles of therapy were considered. The
MTD was defined as the dose level at which no more than
one out of six patients experienced a DLT. Once this dose
level was established, additional patients will be enrolled
(maximum of 12) to gain additional experience with the
combination. The MTD represents the dose recom-
mended for further studies. DLTs were defined as any of
the following: grade 4 neutropenia lasting at least 3 days
or grade 3 or 4 neutropenia associated with fever ≥
38.1°C; grade 4 thrombocytopenia lasting at least 3 days,
grade 4 anemia; any grade 3 or 4 nonhematologic toxicity
except alopecia, gastrointestinal toxicity, and palmar-
plantar erythrodysesthesia (hand-foot syndrome); grade 3
or 4 nausea, vomiting, or mucositis; grade 3 and 4
diarrhea or a second occurrence of grade 2 diarrhea; grade
Table 1: Patient Characteristics
Characteristics No patients
ECOG performance status
01 0
11 1
26
Age, years
Median 68
Range 49–88
Men/Women 9/18
Primary cancer
Colorectal 8
Breast 12
Gastric 1
Pancreas 2
Others 4
Prior chemotherapy
No of patients 21
Range per patient 1–4
Prior radiotherapy 12
Prior endocrine therapy 6
Prior 5-FU 14
No prior therapy 6BMC Cancer 2006, 6:42 http://www.biomedcentral.com/1471-2407/6/42
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2 or 3 hand-foot syndrome not reduced to grade 1 before
the start of cycle 2; delay of ≥ 14 days in initiating the sec-
ond or the third cycle of therapy because of persistent tox-
icity of grade 2 or higher.
Dose modifications
The capecitabine dose was interrupted or modified in
spite of observed toxicity. There was no dose modification
for grade 1 toxicity. For grade 2 toxicity that persisted
despite symptomatic treatment, capecitabine was with-
held until resolution to grade 0 or 1 and then restarted at
the same dose. If the grade 2 toxicity recurred or any grade
3 toxicity, capecitabine was withheld until resolution to
grade 0 or 1 and then restarted at the preceding dose. For
grade 4 toxicity, capecitabine was discontinued unless
considered by the investigator to be in patient's best inter-
est, e.g. a responding patient, to continue at a lower dose
level. In any case, patients who experienced DLT could be
continued on treatment at a modified dose at the discre-
tion of the treating physician if they seemed to be benefit-
ing from the therapy.
Pretreatment and follow-up studies
All patients had a baseline history and full physical exam-
ination with radiologic and laboratory evaluations. His-
tory, physical examination, and laboratory tests were
repeated on day 1 of each cycle of therapy. Assessment of
toxicity and hematology tests were performed weekly dur-
ing each cycle of therapy [during and after the study
period]. Response was assessed after two cycles of treat-
ment (day 43) according to RECIST response criteria [20].
Responding patients or those with stable disease could
continue treatment for a further four cycles of intermittent
chronomodulated therapy with assessment of tumor
response after four and six cycles (day 85 and 127, respec-
tively). Patients who responded or had stable disease after
six cycles could continue treatment at the discretion of the
investigator.
Results
Patients
The characteristics of the 27 patients enrolled onto this
study are listed in Table 1. The median age was 68 years
(range, 49 to 88 years) and the median Eastern Coopera-
tive Oncology Group (ECOG) performance status was 1
(range, 0 to 2). All of them except for six patients had pre-
viously received chemotherapy. 14 patients had previ-
ously received 5-fluorouracil-based chemotherapy. All
patients completed the first two cycles of therapy and
were, therefore, assessable for toxicity.
Toxicity
The most common toxicities observed during the first two
cycles of chemotherapy are listed in Table 2. No episodes
of DLT were observed at capecitabine doses of 1,500/
1,750/2,000/2,250/2,500 mg/m2. Only one patient
treated at capecitabine dose of 2,750 mg/m2, met proto-
col-specified DLT criteria (grade 4 fatigue). 9 patients were
treated at capecitabine dose of 2,750 mg/m2 for a total of
49 cycles and median number of 5 cycles per patient
(Table 3). At this dose step (2,750 mg/m2) we didn't
observe any grade 3 or 4 toxicity (with the exception of
one episode of grade 4 fatigue) during the first two cycles,
but we observed two patients (22.2%) with grade 2 diar-
rhoea, two patients (22.2%) with grade 2 HFS, and two
patients (22.2%) with grade 2 fatigue. All patients
included in this dose step received the first two cycles at
full doses without any dose reduction.
The hematologic and non-Hematologic toxicities cumula-
tive over all cycles are reported in Table 4. At capecitabine
dose level of 2,750 mg/m2 we observed the following
severe toxicities: 1 episode of diarrhoea grade 3 (11.1%),
1 episode of HFS grade 4 (11.1%) and 1 case of liver tox-
icity grade 3 (11.1%), all resolved after dose reduction.
Hematologic toxicity was generally mild, with no patient
experiencing clinically significant myelosuppression.
Moreover, two patients required chemotherapy interrup-
tion because of severe or unresolved toxicity (respectively,
1 patient after three cycles for fatigue grade 3 and another
patient after four cycles for cutaneous toxicity grade 3). At
the same dose step 3 patients (33.3%) of the 9 included
required (cycle 3 or higher) dose reduction or delay for
toxicity. Despite the 2-week duration of dosing and the
high dose level of capecitabine (2,750 mg/m2), few
patients (3 patients, 33.3%) experienced clinically signifi-
cant hand-foot syndrome (grade 2 or higher), no patients
experienced febrile neutropenia or required platelet trans-
Table 3: Duration of treatment
Dose level [mg/mq/die] No cycles administered [1 cycle = 
21 days]
No. of patients No. cycles per patient median 
[range]
1500 21 3 5 [2–14]
1750 33 3 10 [4–19]
2000 24 3 3 [2–19]
2250 24 3 8 [5–11]
2500 28 6 7 [2–10]
2750 49 9 5 [2–12]BMC Cancer 2006, 6:42 http://www.biomedcentral.com/1471-2407/6/42
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fusion, and no patients reported episodes of severe nau-
sea/vomiting or stomatitis (Table 4). The MTD was
defined as the dose level at which no more than one of six
patients experienced a DLT. Once this dose level was
established, additional patients were enrolled (3 patients)
to gain additional experience with the combination.
Based on the occurrence of only one episode of DLT
(fatigue grade 4) during the first two cycles and the ability
to deliver the majority of successive cycles without dose
modification or delay, we recommend doses of chrono-
modulated capecitabine of 2,750 mg/m2 for further eval-
uation in phase II studies.
Table 2: Hematologic and Non-Hematologic Toxicities related to treatment in the first two cycles
No.patients who experienced toxicity, at maximum grade per patient, at each dose 
level, mg/mq/die
Toxicity NCIC-CTC 
grade
1500 1750 2000 2250 2500 2750
N a u s e a / v o m i t i n g 0 23225 4
1 10110 4
2 00001 1
3 *00000 0
4 *00000 0
D i a r r h o e a 0 23323 3
1 10001 4
2 00012 2
3 *00000 0
4 *00000 0
L i v e r  T o x i c i t y 0 32326 6
1 01010 3
2 00000 0
3 *00000 0
4 *00000 0
S t o m a t i t i s 0 33225 6
1 00111 3
2 00000 0
3 *00000 0
4 *00000 0
H F S 0 32324 4
1 01011 3
2 00001 2
3 *00000 0
4 *00000 0
F a t i g u e 0 22103 2
1 01221 4
2 10012 2
3 *00000 0
4 *00000 1
L e u c o - n e u t r o p e n i a 0 22223 6
1 01001 1
2 10110 1
3 00001 1
4 *00000 0
T h r o m b o c y t o p e n i a 0 23235 6
1 00001 2
2 10100 1
3 00000 0
4 *00000 0
A n e m i a 0 12123 7
1 01113 1
2 20100 1
3 00000 0
4 *00000 0BMC Cancer 2006, 6:42 http://www.biomedcentral.com/1471-2407/6/42
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Although assessment of tumor response was not a pri-
mary objective of this study, patients were evaluated for
tumor response after every two cycles of treatment. We
observed 6 partial responses (PR) in breast cancer patients
and 3 PR in colorectal cancer patients. The occurrence of
responses in the colon cancer patient's subset is of partic-
ular note because all had previously received fluoropyri-
midine-based therapy. Moreover, the median number of
previous chemotherapeutic lines in responder patients
was 2 (range, 0–4).
Discussion
This study reports the first phase I experienced with
chronomodulated administration of capecitabine. In the
Table 4: Hematologic and Non-Hematologic Toxicities cumulative over all cycles
No. patients who experienced toxicity, at maximum grade per patient, at each dose level, 
mg/mq/die
Toxicity NCIC-CTC 
grade
1500 1750 2000 2250 2500 2750
Nausea/vomiting 0 2 2 2 2 4 4
111111 3
200001 2
3 * 00000 0
4 * 00000 0
D i a r r h o e a 023303 3
110020 3
200012 2
3 * 000011
4 * 00000 0
L i v e r  T o x i c i t y 022224 6
101001 1
210001 1
3* 0 0 110 1
4 * 00000 0
S t o m a t i t i s 032125 4
101211 4
200000 1
3 * 00000 0
4 * 00000 0
H F S 032312 3
100010 2
200013 3
3* 0 1 001 0
4 * 00000 1
F a t i g u e 020102 2
102222 1
211012 5
3 * 00000 0
4 * 00000 1
Leuco-neutropenia 0 2 2 2 2 2 4
100003 1
211110 2
300001 2
4 * 00000 0
Thrombocytopenia 0 2 2 2 3 4 6
100002 2
210100 1
301000 0
4 * 00000 0
A n e m i a 011101 5
102124 3
220111 1
300000 0
4 * 00000 0BMC Cancer 2006, 6:42 http://www.biomedcentral.com/1471-2407/6/42
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phase I studied by Mackean and collegues [17], capecitab-
ine was administered in monotherapy twice daily, each
cycle administered for 2 weeks followed by 1 week of rest.
Thirty-four patients with advanced and/or metastatic
solid tumors, all of whom except three patients were pre-
treated, were treated at dose levels from 502 to 3,514 mg/
mq daily. They established that 3,000 mg/mq was not tol-
erated and they defined 2,510 mg/mq daily as the dose for
phase II study. In this study the main drug-related toxici-
ties were HFS and gastrointestinal. In the present study the
rational of capecitabine administration especially in noc-
turnal hours (1/4 dose at 8 a.m., 1/4 dose at 6:00 p.m. and
2/4 dose at 11:00 p.m.) was just based on the attempt to
mime 5-FU chronomodulated infusion. For this reason
we decided to attempt a phase I study with the aim of
establishing the MTD of chronomodulated capecitabine
and the suggested dose for phase II studies. Interestingly,
we observed that the chronomodulated way of capecitab-
ine administration was safe and well tolerated in the
majority of our patients. In fact, we reported only one epi-
sode of DLT in the nine patients included in the last dose
step of capecitabine. For this reason, we recommended
the dose of 2,750 mg/m2as the dose of capecitabine sug-
gested for phase II studies. The main drug-related toxici-
ties at dose step were HFS and gastrointestinal, all of
which were reversible and manageable with appropriate
dose interruptions and modifications. The high degree of
tolerability of the intermittent chronomodulated sched-
ule was also confirmed with a median number of five
cycles (ie, 105 days) in patients who received 2,750 mg/
m2 daily. Indeed, nine patients with a response or stable
disease continued after the initial 9 weeks (three cycles)
up to a maximum of 19 cycles (399 + days). The favorable
toxicity profile of our regimen may have occurred because
of the circadian organization of fluoropyrimidine metab-
olism, excretion and therapeutic targets. However, it could
be also related to the thrice-daily schedule rather than the
usual twice daily administration. We were encouraged to
observe significant antitumor activity in this heavily pre-
treated patient population. Six breast cancer patients and
3 colorectal cancer patients obtained partial responses.
Disease stabilization was also observed in 8 patients who,
therefore, received multiple cycles of treatment. Phase II
studies are now being planned for patients with breast
cancer and colorectal cancer to further define the antitu-
mor activity and tolerability of this regimen. Pharmaco-
logic studies were not performed in this study, but it is
likely that such studies would have contributed much
information at this point in the development of this regi-
men. For this reason, a pharmacological study is strongly
suggested. In conclusion, these results clearly highlight
the need for new phase II trials to verify the real clinical
impact of this new way of chronomodulated capecitabine
administration in combination with other active drugs in
solid tumors.
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